In Silico Design of Novel Artocarpus altilis-Derived Compounds Targeting the c-Myc/Max Heterodimer

Authors

  • Tomilola Victor Akingbade Department of Biochemistry, University of Ibadan and Computer-Aided Therapeutic Discovery and Design Platform, Federal University of Technology, Nigeria https://orcid.org/0009-0004-3295-8851
  • Ayobami Fidelix Department of Neurosurgery, University of Texas, USA https://orcid.org/0009-0004-1745-7880
  • Jatin Jangra Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, India
  • Olutola Adeyemo Department of Obstetrics and Gynecology, Federal Teaching Hospital, Nigeria
  • Damilola Adeniyi Department of Science Laboratory Technology, The Federal Polytechnic, Nigeria
  • Dolapo Damilola Akinlose Department of Biochemistry, Ekiti State University, Nigeria

DOI:

https://doi.org/10.47852/bonviewMEDIN52024995

Keywords:

c-MYC inhibition, Artocarpus altilis, molecular docking, molecular dynamics, natural compounds, cancer therapeutics

Abstract

The transcription factor c-Myc plays a pivotal role in regulating cell proliferation, growth, apoptosis, metabolism, and differentiation; however, its overexpression is strongly linked to cancer. Due to its intrinsically disordered structure, c-Myc has been inherently challenging to target therapeutically. To exert its oncogenic effects, c-Myc must form a heterodimer with its binding partner Max, enabling DNA binding and transcriptional activation of target genes. Despite decades of research, developing effective c-Myc inhibitors remains challenging due to issues such as low potency and poor pharmacokinetics. Here, we investigate natural compounds derived from Artocarpus altilis as potential c-Myc inhibitors using computational methods. From screening 81 bioactive compounds, four candidates demonstrated stronger binding affinities to c-Myc than the reference drug Alisertib: Ellagic acid, Artonin M, Cycloaltilisin 7, and Broussoflavonol F. Molecular dynamics simulations showed Broussoflavonol F had exceptional stability and the most favorable MM-PBSA binding energy. Pharmacokinetic analysis suggested promising drug properties, though some toxicity risks were noted. These findings highlight Artocarpus altilis-derived compounds, particularly Broussoflavonol F, as promising c-Myc inhibitors. This study provides a foundation for experimental validation and optimization, offering new therapeutic potential against c-Myc-driven cancers.

 

Received: 10 December 2024 | Revised: 26 February 2025 | Accepted: 23 April 2025

 

Conflicts of Interest

The authors declare that they have no conflicts of interest to this work.

 

Data Availability Statement

The data that support this work are available upon reasonable request to the corresponding author.

 

Author Contribution Statement

Tomilola Victor Akingbade: Methodology, Software, Validation, Formal analysis, Investigation, Resources, Data curation, Writing – original draft, Writing – review & editing, Visualization, Supervision, Project administration. Ayobami Fidelix: Conceptualization, Methodology, Software, Validation, Formal analysis, Investigation, Resources, Writing – original draft, Writing – review & editing, Supervision, Project administration. Jatin Jangra: Software, Investigation, Visualization. Olutola Adeyemo: Data curation, Writing – original draft, Writing – review & editing. Damilola Adeniyi: Validation, Data curation, Writing – original draft, Writing – review & editing. Dolapo Damilola Akinlose: Formal analysis, Resources, Writing – original draft, Writing – review & editing.


Downloads

Published

2025-05-08

Issue

Section

Research Articles

How to Cite

Akingbade, T. V., Fidelix, A., Jangra, J., Adeyemo, O., Adeniyi, D., & Akinlose, D. D. (2025). In Silico Design of Novel Artocarpus altilis-Derived Compounds Targeting the c-Myc/Max Heterodimer. Medinformatics. https://doi.org/10.47852/bonviewMEDIN52024995